Ethereum Drops Below This Key Level; Neo Becomes Top Loser

Bitcoin (CRYPTO: BTC) moved lower, with the cryptocurrency prices falling below the key $30,000 level on Friday. Ethereum (CRYPTO: ETH) also moved lower, falling below the key $2,100 mark this morning.

Bitcoin (CRYPTO: BTC) moved lower, with the cryptocurrency prices falling below the key $30,000 level on Friday.

Ethereum (CRYPTO: ETH) also moved lower, falling below the key $2,100 mark this morning.

The NY Empire State Manufacturing Index surged to 10.8 in April from -24.6 in the previous, beating market expectations of -18.

Render Token (CRYPTO: RNDR) was the top gainer over the prior 24 hours, while Neo (CRYPTO: NEO) turned out to be the biggest loser.

At the time of writing, the global crypto market cap fell to $1.26 trillion, recording a 24-hour decline of 1.2%. BTC was trading lower by 2.5% at $29,534 while ETH fell by around 0.4% to $2,082 on Monday.

Here are the top ten crypto gainers and losers over the past 24 hours:

Gainers

  • Render Token (CRYPTO: RNDR)

Price: $1.91
24-hour gain: 12.8%

  • Avalanche (CRYPTO: AVAX)

Price: $20.74
24-hour gain: 8.4%

  • Loopring (CRYPTO: LRC)

Price: $0.416
24-hour gain: 8.1%

  • Fantom (CRYPTO: FTM)

Price: $0.535
24-hour gain: 6%

  • Internet Computer (CRYPTO: ICP)

Price: $6.10
24-hour gain: 5.6%

Losers

  • Neo (CRYPTO: NEO)

Price: $13.00
24-hour drop: 6.3%

  • Klaytn (CRYPTO: KLAY)

Price: $0.2528
24-hour drop: 4.9%

  • Conflux (CRYPTO: CFX)

Price: $0.3597
24-hour drop: 4.3%

  • Kava (CRYPTO: KAVA)

Price: $0.9222
24-hour drop: 3.3%

  • Immutable (CRYPTO: IMX)

Price: $1.15
24-hour drop: 3%

Read This Next: Top 5 Health Care Stocks That May Fall Off A Cliff This Quarter

Total
0
Shares
Related Posts
Read More

Evolus Enters Into Licensing Agreement With Symatese To Exclusively Distribute Next-Generation Dermal Fillers In Europe; Evolus Will Pre-Announce Preliminary, Unaudited Q4 And FY23 Results And Revenue Guidance For 2024 In January

Exclusive Distributor Agreement with Symatese Broadens Evolus' Dermal Filler Footprint Beyond the U.S. to Include the United Kingdom and EuropeEuropean Regulatory Approvals Anticipated in Second Half of 2024Company

EOLS